Reata Pharmaceuticals RETA Stock
Reata Pharmaceuticals Price Chart
Reata Pharmaceuticals RETA Financial and Trading Overview
Reata Pharmaceuticals stock price | 172.36 USD |
Previous Close | 102.22 USD |
Open | 100.96 USD |
Bid | 0 USD x 1000 |
Ask | 0 USD x 1100 |
Day's Range | 87.66 - 100.99 USD |
52 Week Range | 18.47 - 106.69 USD |
Volume | 2.25M USD |
Avg. Volume | 759.16K USD |
Market Cap | 3.52B USD |
Beta (5Y Monthly) | 1.515845 |
PE Ratio (TTM) | N/A |
EPS (TTM) | 0 USD |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 116.2 USD |
RETA Valuation Measures
Enterprise Value | 3.71B USD |
Trailing P/E | N/A |
Forward P/E | -22.182467 |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 2348.154 |
Price/Book (mrq) | N/A |
Enterprise Value/Revenue | 2480.938 |
Enterprise Value/EBITDA | -11.486 |
Trading Information
Reata Pharmaceuticals Stock Price History
Beta (5Y Monthly) | 1.515845 |
52-Week Change | 202.45% |
S&P500 52-Week Change | 20.43% |
52 Week High | 106.69 USD |
52 Week Low | 18.47 USD |
50-Day Moving Average | 94.4 USD |
200-Day Moving Average | 56.51 USD |
RETA Share Statistics
Avg. Volume (3 month) | 759.16K USD |
Avg. Daily Volume (10-Days) | 714.91K USD |
Shares Outstanding | 33.04M |
Float | 26.69M |
Short Ratio | 4.15 |
% Held by Insiders | 3.82% |
% Held by Institutions | 101.73% |
Shares Short | 4.35M |
Short % of Float | 17.76% |
Short % of Shares Outstanding | 11.58% |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 0% |
Operating Margin (ttm) | -21673.34% |
Gross Margin | 0% |
EBITDA Margin | 0% |
Management Effectiveness
Return on Assets (ttm) | -35.78% |
Return on Equity (ttm) | N/A |
Income Statement
Revenue (ttm) | 1.5M USD |
Revenue Per Share (ttm) | 0.04 USD |
Quarterly Revenue Growth (yoy) | -78.70% |
Gross Profit (ttm) | -167627000 USD |
EBITDA | -323340000 USD |
Net Income Avi to Common (ttm) | -354176000 USD |
Diluted EPS (ttm) | -10.16 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 320.96M USD |
Total Cash Per Share (mrq) | 8.55 USD |
Total Debt (mrq) | 117.93M USD |
Total Debt/Equity (mrq) | N/A |
Current Ratio (mrq) | 6.091 |
Book Value Per Share (mrq) | -3.482 |
Cash Flow Statement
Operating Cash Flow (ttm) | -227531008 USD |
Levered Free Cash Flow (ttm) | -143585376 USD |
Profile of Reata Pharmaceuticals
Country | United States |
State | TX |
City | Plano |
Address | 5320 Legacy Drive |
ZIP | 75024 |
Phone | 972 865 2219 |
Website | https://www.reatapharma.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 321 |
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease (CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone to treat Friedreich's ataxia; and conduct various form of CKD, such as, type 1 and type 2 diabetic CKD, type 1 and type 2 diabetic CKD, hypertensive CKD, focal segmental glomerulosclerosis, and others. It is also developing RTA 901 for neurological diseases; and bardoxolone for the treatment of autosomal dominant polycystic kidney disease. In addition, the company has a strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize bardoxolone for renal, cardiovascular, diabetes, and various other related metabolic indications in Japan, China, Hong Kong, Macao, South Korea, Taiwan, Thailand, Singapore, the Philippines, Malaysia, Indonesia, Brunei, Vietnam, Laos, Myanmar, and Cambodia; AbbVie Inc. to jointly research, develop, and commercialize all second- and later-generation Nrf2 activators for all indications other than renal, cardiovascular, and metabolic indications. Reata Pharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Plano, Texas.
Q&A For Reata Pharmaceuticals Stock
What is a current RETA stock price?
Reata Pharmaceuticals RETA stock price today per share is 172.36 USD.
How to purchase Reata Pharmaceuticals stock?
You can buy RETA shares on the NasdaqGM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Reata Pharmaceuticals?
The stock symbol or ticker of Reata Pharmaceuticals is RETA.
Which industry does the Reata Pharmaceuticals company belong to?
The Reata Pharmaceuticals industry is Biotechnology.
How many shares does Reata Pharmaceuticals have in circulation?
The max supply of Reata Pharmaceuticals shares is 38.1M.
What is Reata Pharmaceuticals Price to Earnings Ratio (PE Ratio)?
Reata Pharmaceuticals PE Ratio is 0.00000000 now.
What was Reata Pharmaceuticals earnings per share over the trailing 12 months (TTM)?
Reata Pharmaceuticals EPS is 0 USD over the trailing 12 months.
Which sector does the Reata Pharmaceuticals company belong to?
The Reata Pharmaceuticals sector is Healthcare.
Reata Pharmaceuticals RETA included in indexes
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
---|
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
---|---|---|---|---|---|---|---|
{{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
NASDAQ Composite IXIC | 16103.45 USD — |
+0.82
|
4.52B USD — | 16094.17 USD — | 16247.59 USD — | — - | 4.52B USD — |
NASDAQ Global Market Composite NQGM | 2185.85 USD — |
-0.31
|
— — | 2177.48 USD — | 2204.21 USD — | — - | — — |
Stlmt ID NASDAQ Biotechnology NBX | 4604.4 USD — |
-2.98
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
Nasdaq US 700 Small Cap Index NQUS700SC | 2078.81 USD — |
-0.4
|
— — | 2075.76 USD — | 2093.28 USD — | — - | — — |
Nasdaq AlphaDEX Multi Cap Growt NQDXUSMLTCG | 2568.29 USD — |
+0.16
|
— — | 2566.7 USD — | 2581.47 USD — | — - | — — |
NASDAQ Biotechnology NBI | 4337.34 USD — |
-0.65
|
— — | 4335.84 USD — | 4376.86 USD — | — - | — — |
NASDAQ HealthCare IXHC | 986.88 USD — |
-0.25
|
— — | 986.44 USD — | 994.67 USD — | — - | — — |
- {{ link.label }} {{link}}